IFF reported solid financial results for FY2025, meeting its commitments despite a challenging environment, and advanced its strategic priorities including portfolio optimization through divestitures and the launch of a sale process for the Food Ingredients segment. The company is focused on profitable growth in 2026, driven by innovation and reinvestment, while navigating macroeconomic uncertainty.
Full year 2025 reported net sales of $10.89 billion, a decrease of (5)% compared to the prior year, but on a comparable currency neutral basis, sales increased 2%.
neutralFull year 2025 adjusted operating EBITDA was $2.086 billion, and on a comparable currency neutral basis, increased 7%, led by volume growth, productivity gains and favorable net pricing.
positiveFourth quarter 2025 comparable currency neutral sales increased 1% and comparable currency neutral adjusted operating EBITDA increased 7% led by productivity gains.
positiveTaste segment comparable currency neutral adjusted operating EBITDA grew 10% for the full year and 17% in Q4, driven by favorable net pricing, volume growth and productivity gains.
positiveHealth & Biosciences segment comparable currency neutral adjusted operating EBITDA grew 7% for the full year and 20% in Q4, led by volume growth and productivity gains.
positiveReported net sales for the full year 2025 decreased by (5)% to $10.89 billion, and by (7)% to $2.59 billion in Q4, compared to the prior year periods.
negativeReported net loss for the full year 2025 was $(372) million, or $(1.46) per diluted share, a significant decline from a net income of $263 million in the prior year.
negativeFood Ingredients segment comparable currency neutral sales decreased (3)% for the full year and (4)% in Q4, impacted by softness in Protein Solutions and proactive exit of low margin business.
attentionFood Ingredients segment comparable currency neutral adjusted operating EBITDA declined (11)% in Q4, as productivity gains were more than offset by lower volumes and unfavorable net price.
negativePharma Solutions segment reported sales decreased (65)% for both the full year and Q4, reflecting the divestiture of the business.
negativeFull year 2025 free cash flow was $256 million, a decrease from $1.07 billion in the prior year.
negativeMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
Taste | N/A | — | — | — | +4.0% |
Food Ingredients | N/A | — | — | — | -3.0% |
Health & Biosciences | N/A | — | — | — | +3.0% |
Scent | N/A | — | — | — | +3.0% |
Pharma Solutions | N/A | — | — | — | +12.0% |
| Total Revenue | $0.00M | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment.
We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth.
Through several divestitures and the recent launch of a sale process for our Food Ingredients segment, we sharpened our strategic focus and improved our financial flexibility, allowing us to direct resources to our highest-value businesses.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.